Breaking News
New York Cannot Ban Federal Agents From Wearing Masks, Judge Rules
The New McCarthys: 40% Of Professors Against Hiring A Trump-Voter
Trump Warns Iran This Is Their Fourth-To-Last Chance At Peace
US sends more intel assets to Cuba
Top Tech News
Voyager 1 approaches one light day from Earth
Visual Implants
Renewable Energy Breakthrough! World's Most Efficient Tesla Turbine System
I Told You So
Meet Sunbird, a nuclear fusion-powered space tug concept from Pulsar Fusion.
China and Russia launch 29-nation AI alliance to rival western control of technology
BREAKING: China has begun manufacturing domestically developed Immersion Deep...
Idaho's High Desert Becomes Hot Spot For Nuclear Power Revolution
The World's Largest Electric Aircraft Is About to Take Its First Flight
Tesla Cybercabs and Superchargers Will Act as Mini Cell Towers for SpaceX Starlink
Oligodendrocyte progenitor cells repair damaged spine in humans in clinical trial...
AST's technology comes from one of the leading companies in regenerative medicine, BioTime, Inc., (NYSE: BTX) which spun off Asterias Biotherapeutics a few years ago and is also its largest shareholder. It is also worth pointing out that BioTime's CEO, Dr. Michael West, is one of the world's leading experts in regenerative and stem cell research
Asterias Biotherapeutics is a leading biotechnology company in the emerging field of regenerative medicine. The company's proprietary cell therapy programs are based on its immunotherapy and pluripotent stem cell platform technologies. Asterias is presently focused on advancing three clinical-stage programs which have the potential to address areas of very high unmet medical need in the fields of oncology and neurology.
Dr Michael West will use regenerative stem cell medicine to solve the primary diseases of aging.